Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Stopped The study met its prespecified futility criteria during the prespecified interim futility analysis after enrolling the first cohort of 10 patients.
Conditions
- Kidney Medullary Carcinoma
- Loss of INI 1 Protein Expression
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
Interventions
- BIOLOGICAL: Ipilimumab
- BIOLOGICAL: Nivolumab
Sponsor
M.D. Anderson Cancer Center
Collaborators